Get the Stockscreener App
8.20
2.12%
0.17
Cogent Biosciences Inc stock is traded at $8.20, with a volume of 1.44M.
It is up +2.12% in the last 24 hours and up +4.59% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
See More
Previous Close:
$8.03
Open:
$8.05
24h Volume:
1.44M
Relative Volume:
0.97
Market Cap:
$905.79M
Revenue:
-
Net Income/Loss:
$-227.05M
P/E Ratio:
-3.3065
EPS:
-2.48
Net Cash Flow:
$-177.93M
1W Performance:
+11.26%
1M Performance:
+4.59%
6M Performance:
-4.76%
1Y Performance:
+78.65%
1-Day Range:
$7.7428
$8.24
1-Week Range:
$7.7428
$8.72
52-Week Range:
$4.28
$12.61
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
8.20 | 905.79M | 0 | -227.05M | -177.93M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Assenagon Asset Management S.A. Sells 133,515 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent and ModivCare gain after insider purchases - MSN
How to Take Advantage of moves in (COGT) - Stock Traders Daily
Short Interest in Cogent Biosciences, Inc. (NASDAQ:COGT) Expands By 9.3% - MarketBeat
Cogent Biosciences Appoints James P. Geygan as Independent Director - Defense World
Hennion & Walsh Asset Management Inc. Buys 103,293 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data - Seeking Alpha
This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year - Yahoo Finance
Cole Pinnow Bought 2,085% More Shares In Cogent Biosciences - Yahoo Finance
HC Wainwright Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $14.00 - Defense World
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Price Target at $14.83 - Defense World
Cogent Biosciences chief commercial officer buys $332,412 in stock By Investing.com - Investing.com Canada
Cogent stock ModivCare stock up on insider buys (COGT:NASDAQ) - Seeking Alpha
Cogent Biosciences (NASDAQ:COGT) Shares Gap UpHere's What Happened - MarketBeat
Cogent Biosciences chief commercial officer buys $332,412 in stock - Investing.com
HC Wainwright Has Lowered Expectations for Cogent Biosciences (NASDAQ:COGT) Stock Price - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.83 Average Target Price from Analysts - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Receives Neutral Rating from Wedbush - Defense World
Wedbush Reiterates Neutral Rating for Cogent Biosciences (NASDAQ:COGT) - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 11.9%Here's Why - MarketBeat
Cogent Biosciences Announces Planned 2025 Milestones for - GlobeNewswire
Cogent Biosciences sets key 2025 milestones for drug trials By Investing.com - Investing.com South Africa
Cogent Biosciences sets key 2025 milestones for drug trials - Investing.com India
Cogent Biosciences Sets Major 2025 Milestones: Three Phase 3 Results, First NDA Submission Planned - StockTitan
Objective long/short (COGT) Report - Stock Traders Daily
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Cogent Biosciences CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Cogent Biosciences (NASDAQ:COGT) Shares Up 8.8%Still a Buy? - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 2.5%What's Next? - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Holdings Trimmed by Jane Street Group LLC - Defense World
Jane Street Group LLC Reduces Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
(COGT) Investment Report - Stock Traders Daily
Geode Capital Management LLC Buys 300,062 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Geode Capital Management LLC Purchases 300,062 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Barclays PLC Boosts Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Barclays PLC Has $1.90 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.83 Consensus Target Price from Analysts - Defense World
State Street Corp Sells 605,500 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 4.4%What's Next? - MarketBeat
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation - Simply Wall St
Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Lowered by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Why Is Cogent Biosciences Stock Trading Higher On Monday? - AOL
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Increase in Short Interest - MarketBeat
What is HC Wainwright’s Forecast for COGT FY2024 Earnings? - Defense World
HC Wainwright Issues Pessimistic Estimate for COGT Earnings - MarketBeat
Needham Downgrades Cogent Biosciences (COGT) - MSN
Cogent Biosciences (NASDAQ:COGT) Receives "Buy" Rating from HC Wainwright - MarketBeat
Needham & Company LLC Downgrades Cogent Biosciences (NASDAQ:COGT) to Hold - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Charles Schwab Investment Management Inc. Has $8.92 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):